The short answer
Cyclobenzaprine has not been shown to create a need for Valeriana officinalis or a particular valerian dosing schedule. Added drowsiness is a reason to review co-use, but no protective spacing interval is established.
What this answer covers
Exact Valeriana officinalis species; root preparations, extracts and doses vary. Do not equate this with an unidentified valerian-root node.
- Supplement or preparation
- Valeriana officinalis
- Medication ingredient
- cyclobenzaprine
No demonstrated new supplement requirement
The inspected evidence does not show that cyclobenzaprine depletes something replaced by valerian or makes valerian necessary. A possible interaction does not establish a nutritional or therapeutic requirement.
The practical concern is alertness
Valerian guidance cautions about sedating substances, and cyclobenzaprine can intensify CNS depression with other agents. This supports review of co-use without proving a timing rule.
The efficacy evidence does not define a schedule
A trial including valerian did not establish sleep benefit and did not test cyclobenzaprine. Neither a positive sleep claim nor a null result supplies a safe dose or spacing interval for the combination.
Follow the prescribed formulation’s instructions
Show the pharmacist the valerian preparation and whether cyclobenzaprine is swallowed or sublingual. Follow that medicine’s administration directions, but do not treat them as proof that taking valerian earlier or later prevents impairment.
Evidence and practical considerations
Timing & monitoring
Current need/timing claim lacks evidence of a new requirement or validated schedule. Separate conditional additive-drowsiness precaution does not establish supplement need or protective spacing.
- Exact scope
- Exact Valeriana officinalis species; root preparations, extracts and doses vary. Do not equate this with an unidentified valerian-root node. with Cyclobenzaprine21949 IN; hydrochloride swallowed IR/ER and sublingual products with formulation-specific indications.
- Medication form and route
- oral medication; sublingual medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonin-syndrome warnings; concomitant MAOIs and14days after stopping contraindicated.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not extended-release or sublingual dosing; supplement-specific risk unmeasured.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonergic precautions; MAOI contraindication.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Different release/directions from immediate-release and sublingual products.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS depression and serotonergic precautions; MAOI contraindication retained.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not swallowed-tablet dosing; sublingual product administration instructions are not a universal supplement-separation rule.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 6: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact cyclobenzaprine article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: efc3d2b2c5e034f1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.